E-resources
PDF-
Murthy, Rashmi K; Loi, Sherene; Okines, Alicia; Paplomata, Elisavet; Hamilton, Erika; Hurvitz, Sara A; Lin, Nancy U; Borges, Virginia; Abramson, Vandana; Anders, Carey; Bedard, Philippe L; Oliveira, Mafalda; Jakobsen, Erik; Bachelot, Thomas; Shachar, Shlomit S; Müller, Volkmar; Braga, Sofia; Duhoux, Francois P; Greil, Richard; Cameron, David; Carey, Lisa A; Curigliano, Giuseppe; Gelmon, Karen; Hortobagyi, Gabriel; Krop, Ian; Loibl, Sibylle; Pegram, Mark; Slamon, Dennis; Palanca-Wessels, M. Corinna; Walker, Luke; Feng, Wentao; Winer, Eric P
The New England journal of medicine, 02/2020, Volume: 382, Issue: 7Journal Article
In women with HER2-positive metastatic breast cancer who had previously received HER2-targeted therapy, tucatinib, a new selective inhibitor of the HER2 tyrosine kinase, was added to trastuzumab and capecitabine and compared with trastuzumab and capecitabine plus placebo. Progression-free survival at 1 year was 33% with tucatinib and 12% with placebo.
